Black Swan Sale

50% Off Elite

Get our most powerful screeners, new charting tools, and the fastest ad-
free experience at our best price ever. This deal may never happen again.

CYPH

Cypherpunk Technologies Inc

Nov 19 • 04:00PM ET

2.94

-0.03 -1.01 %

Financial • Asset Management • USA • NASD

Peers: AFMD XNCR MTEM KZR ADAP PRQR NKTR RIGL BLRX BGMS

| Held by: PINK MEME VTI VXF NMBL

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-1.23	Insider Own	27.77%	Shs Outstand	41.44M	Perf Week	43.41%
Market Cap	166.56M	Forward P/E	-	EPS next Y	-0.15	Insider Trans	-9.31%	Shs Float	40.92M	Perf Month	505.44%
Enterprise Value	156.91M	PEG	-	EPS next Q	-0.07	Inst Own	13.01%	Short Float	7.11%	Perf Quarter	969.09%
Income	-50.81M	P/S	-	EPS this Y	49.11%	Inst Trans	-2.20%	Short Ratio	0.13	Perf Half Y	713.50%
Sales	0.00M	P/B	45.21	EPS next Y	84.15%	ROA	-132.94%	Short Interest	2.91M	Perf YTD	2.26%
Book/sh	0.07	P/C	17.19	EPS next 5Y	-	ROE	-196.76%	52W High	3.58 -17.88%	Perf Year	7.30%
Cash/sh	0.17	P/FCF	-	EPS past 3/5Y	27.46% 34.28%	ROIC	-1885.42%	52W Low	0.22 1222.54%	Perf 3Y	-58.30%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	48.17% 34.95%	Perf 5Y	-80.91%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	36.27%	Oper. Margin	-	ATR (14)	0.45	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	1.21	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	79.14	Recom	3.00
Dividend Gr. 3/5Y	- -	Current Ratio	1.21	EPS Q/Q	81.93%	SMA20	176.52%	Beta	-1.87	Target Price	5.50
Payout	-	Debt/Eq	0.01	Sales Q/Q	-	SMA50	313.93%	Rel Volume	1.48	Prev Close	2.97
Employees	52	LT Debt/Eq	0.00	Earnings	Nov 12 BMO	SMA200	549.02%	Avg Volume	22.10M	Price	2.94
IPO	Jan 25, 2017	Option/Short	Yes / No	EPS/Sales Surpr.	- -	Trades		Volume	32,980,632	Change	-1.01%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-29-25	Downgrade	Robert W. Baird	Outperform → Neutral	$9 → $1.25
Jan-29-25	Downgrade	H.C. Wainwright	Buy → Neutral
Jun-28-24	Initiated	Rodman & Renshaw	Buy	$8
Oct-04-21	Initiated	Mizuho	Buy	$6
Jun-04-21	Resumed	Robert W. Baird	Outperform	$5
Jun-29-20	Initiated	Piper Sandler	Overweight	$6
Feb-11-20	Initiated	Robert W. Baird	Outperform	$6
Nov-15-19	Downgrade	Raymond James	Outperform → Mkt Perform
Sep-13-19	Resumed	Raymond James	Outperform
Mar-07-17	Initiated	Ladenburg Thalmann	Buy	$18

Nov-18-25 07:00AM	Cypherpunk Purchases Additional $18 Million of ZEC, Bringing Total Network Percentage to 1.43% (PR Newswire) +22.22%
Nov-14-25 09:55AM	Cypherpunk Stock Soars on Zcash Rebrand. Should You Buy the Crypto Penny Stock Here? (Barchart) +56.25%
Nov-12-25 06:08PM	Winklevoss-backed stock halted multiple times after wild 550% rally (TheStreet) +368.57% -14.15%
05:07PM	Leap Therapeutics Surges 300% on $50M Winklevoss-Backed Zcash Bet (CoinDesk)
02:00PM	Billionaire twinsbacked stock surges 100% after buying $50M encrypted Bitcoin (TheStreet)
09:50AM	Loading…
09:50AM	Leap Therapeutics Rebrands as Cypherpunk Technologies to Focus on Zcash (Coinspeaker)
08:00AM	Cypherpunk Technologies (formerly Leap Therapeutics) Reports Third Quarter 2025 Financial Results (PR Newswire)
07:01AM	Zcash Treasury Company Launches With Winklevoss Backing (decrypt)
07:00AM	Leap Therapeutics Rebrands as Cypherpunk; Expands Leadership Team to Drive New Zcash Treasury Strategy (PR Newswire)
Oct-20-25 07:00AM	Leap Therapeutics Presents Final Data from DeFianCe Study at ESMO 2025 (PR Newswire) -5.24%
Oct-09-25 07:00AM	Leap Therapeutics Announces Closing of $58.88 Million Private Placement in Cash Led by Winklevoss Capital to Initiate a Digital Asset Treasury Strategy (PR Newswire) -8.55%
Oct-07-25 09:00AM	Clinical Breakthroughs Converge as Immunotherapy Market Surges Past $136 Billion (PR Newswire) -17.98%
Oct-06-25 10:54AM	Leap Therapeutics Shares Jump on $59M Winklevoss-Led Crypto Deal (CoinDesk) +43.15%
09:00AM	Leap Therapeutics Announces $58.88 Million Private Placement in Cash Commitments Led by Winklevoss Capital to Initiate a Digital Asset Treasury Strategy (PR Newswire)
Sep-25-25 07:00AM	Leap Therapeutics to Present Final Clinical Data from Part B of the DeFianCe Study at the ESMO Congress 2025 (PR Newswire) +12.63%
07:00AM	Loading…
Aug-14-25 07:00AM	Leap Therapeutics Reports Second Quarter 2025 Financial Results (PR Newswire) -28.14%
Jun-23-25 07:00AM	Leap Therapeutics Reports Updated Clinical Data from Sirexatamab Colorectal Cancer Study and Announces Exploration of Strategic Alternatives (PR Newswire) -18.04%
May-13-25 07:00AM	Leap Therapeutics Reports First Quarter 2025 Financial Results (PR Newswire) +6.64%
Apr-25-25 01:00PM	Leap Therapeutics to Present Preclinical Data of FL-501, a Novel GDF-15 Neutralizing Antibody, at the AACR 2025 Annual Meeting (PR Newswire)
Apr-15-25 07:00AM	Leap Therapeutics to Host Virtual KOL Event to Discuss Sirexatamab (DKN-01) in Second-line Patients with Advanced Microsatellite Stable Colorectal Cancer (PR Newswire) +9.77%
Mar-31-25 01:42PM	Leap Therapeutics (LPTX) Conference Call to discuss Updated Data from Part B of the DeFianCe Study Transcript (Seeking Alpha)
Mar-26-25 01:29PM	Penny Stock Leap Therapeutics Unveils Positive Data From Experimental Combo Therapy For Colorectal Cancer (Benzinga) +16.88%
07:05AM	Leap Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results (PR Newswire)
07:00AM	Leap Therapeutics Reports Positive Updated Data from Sirexatamab Colorectal Cancer Study (PR Newswire)
Jan-28-25 07:00AM	Leap Therapeutics Reports Initial Clinical Data from Part B of the DeFianCe Study and Part C of the DisTinGuish Study (PR Newswire) -71.11%
Jan-06-25 07:00AM	Leap Therapeutics to Participate at the 43rd Annual J.P. Morgan Healthcare Conference (PR Newswire)
Nov-26-24 07:00AM	Leap Therapeutics to Participate at Piper Sandler 36th Annual Healthcare Conference (PR Newswire) +5.16%
Nov-13-24 07:00AM	Leap Therapeutics Reports Third Quarter 2024 Financial Results (PR Newswire) -7.69%
Sep-30-24 07:00AM	Leap Therapeutics Announces Completion of Enrollment in Part B of the DeFianCe Study of DKN-01 for the Treatment of Colorectal Cancer Patients (PR Newswire)
Aug-12-24 07:00AM	Leap Therapeutics Reports Second Quarter 2024 Financial Results (PR Newswire)
08:31AM	Loading…
May-13-24 08:31AM	Leap Therapeutics Inc (LPTX) Q1 2024 Earnings: Financial Resilience Amidst Clinical Progress (GuruFocus.com)
07:00AM	Leap Therapeutics Reports First Quarter 2024 Financial Results (PR Newswire)
Apr-29-24 04:01AM	Pipeline Moves: Investigator-led trial of Lillys merestinib in solid tumours terminated (Clinical Trials Arena) -5.54%
Apr-11-24 08:30AM	Leap Therapeutics Announces $40 Million Private Placement (PR Newswire)
Mar-20-24 09:35AM	Here's Why Leap Therapeutics (LPTX) is Poised for a Turnaround After Losing -28.92% in 4 Weeks (Zacks) +15.91%
Mar-18-24 07:00AM	Leap Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results (PR Newswire)
Jan-16-24 05:05PM	Leap Therapeutics to Present New Clinical Data from Part A of DeFianCe Study at the 2024 ASCO Gastrointestinal Cancers Symposium (PR Newswire)
Jan-03-24 07:00AM	Leap Therapeutics to Participate at the 42nd Annual J.P. Morgan Healthcare Conference (PR Newswire)
Jan-02-24 07:00AM	Leap Therapeutics Announces Completion of Enrollment in Randomized Controlled Part C of the DisTinGuish Study of DKN-01 for the Treatment of Gastric Cancer Patients (PR Newswire) +12.67%
Dec-11-23 04:05PM	Leap Therapeutics to Present New Data from Part A of the DeFianCe Study of DKN-01 Plus Bevacizumab and Chemotherapy in Colorectal Cancer Patients at the 2024 ASCO Gastrointestinal Cancers Symposium (PR Newswire) +11.28%
Nov-21-23 07:00AM	Leap Therapeutics to Participate at Piper Sandler 35th Annual Healthcare Conference (PR Newswire) +17.87%
Nov-13-23 07:00AM	Leap Therapeutics Reports Third Quarter 2023 Financial Results (PR Newswire)
Oct-24-23 12:30PM	10 Biotech Stocks Below Cash Value with Key Catalysts on the Horizon: An Analysis (ACCESSWIRE)
Oct-03-23 09:55AM	These 2 Strong Buy Penny Stocks Could Gain Over 500%, Says Baird (TipRanks) +26.92%
Sep-05-23 07:00AM	Leap Therapeutics to Participate at Upcoming Investor Conferences (PR Newswire)
Aug-14-23 07:00AM	Leap Therapeutics Reports Second Quarter 2023 Financial Results (PR Newswire)
Aug-13-23 10:44AM	10 Most Promising Penny Stocks According to Analysts (Insider Monkey)
Jul-12-23 07:00AM	Leap Therapeutics Announces Initiation of Randomized Controlled Part B of the DeFianCe Study of DKN-01 in Colorectal Cancer Patients (PR Newswire) +6.19%
Jun-20-23 12:30PM	Leap Therapeutics Announces Reverse Stock Split (PR Newswire) -23.22%
Jun-04-23 07:11AM	10 Hot Penny Stocks To Buy (Insider Monkey)
May-25-23 05:10PM	Leap Therapeutics to Present Updated Data from Part A of the DisTinGuish Study of DKN-01 Plus Tislelizumab and Chemotherapy in Gastric Cancer Patients at the 2023 ASCO Annual Meeting (PR Newswire) -9.82%
May-15-23 07:00AM	Leap Therapeutics Reports First Quarter 2023 Financial Results (PR Newswire)
Apr-26-23 04:05PM	Leap Therapeutics to Present Updated Data from Part A of the DisTinGuish Study of DKN-01 Plus Tislelizumab and Chemotherapy in Gastric Cancer Patients at the 2023 ASCO Annual Meeting (PR Newswire) +6.37%
Apr-12-23 07:00AM	Leap Therapeutics Announces Completion of Enrollment in Part A of the DeFianCe Study of DKN-01 for the Treatment of Colorectal Cancer Patients (PR Newswire) +17.67%
Apr-04-23 11:10AM	Leap Therapeutics (NASDAQ:LPTX) Will Have To Spend Its Cash Wisely (Simply Wall St.)
Mar-24-23 07:00AM	Leap Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results (PR Newswire)
Mar-17-23 12:26PM	BeiGene Will Not Go Forward With Licensing Pact For Leap Therapeutics' Lead Cancer Candidate (Benzinga) -16.85%
Mar-16-23 04:05PM	Leap Therapeutics Provides Update on BeiGene Option Agreement for DKN-01 (PR Newswire) +6.05%
Jan-17-23 05:13PM	Leap Therapeutics to acquire Pennsylvania biotech in all-stock deal (American City Business Journals) -14.66%
09:24AM	Leap Therapeutics Shares Fall After Flame Biosciences Acquisition (Benzinga)
08:00AM	Leap Therapeutics Acquires Flame Biosciences (PR Newswire)
Jan-11-23 07:00AM	Leap Therapeutics to Present at B. Riley Securities' 3rd Annual Oncology Conference (PR Newswire)
Nov-21-22 07:00AM	Leap Therapeutics to Participate at the Piper Sandler 34th Annual Healthcare Conference (PR Newswire)
Nov-16-22 05:20AM	Leap Therapeutics Third Quarter 2022 Earnings: US$0.13 loss per share (vs US$0.14 loss in 3Q 2021) (Simply Wall St.) -5.12%
Nov-14-22 07:00AM	Leap Therapeutics Reports Third Quarter 2022 Financial Results (PR Newswire) +12.62%
Nov-07-22 08:05AM	Leap Therapeutics to Present Updated Data from the DisTinGuish Study of DKN-01 Plus Tislelizumab and Preclinical Data in Colorectal Cancer Models at the SITC Annual Meeting (PR Newswire)
Oct-26-22 08:19AM	Is Leap Therapeutics (NASDAQ:LPTX) In A Good Position To Deliver On Growth Plans? (Simply Wall St.)
Oct-17-22 07:00AM	Leap Therapeutics Announces First Patient Enrolled in DeFianCe Study of DKN-01 for the Treatment of Colorectal Cancer Patients (PR Newswire)
Oct-12-22 07:00AM	Leap Therapeutics Announces First Patient Enrolled in Part C of Phase 2 DisTinGuish Study of DKN-01 in Combination with Tislelizumab for the Treatment of Gastric or Gastroesophageal Junction Cancer (PR Newswire)
Oct-05-22 08:05AM	Leap Therapeutics to Present Updated Data from the DisTinGuish Study of DKN-01 Plus Tislelizumab and Preclinical Data in Colorectal Cancer Models at the SITC Annual Meeting (PR Newswire)
Sep-27-22 08:15AM	Arthur Tzianabos, Ph.D., June Lee, MD FACCP, and Joseph Loscalzo, MD, Ph.D. Join 5AM Ventures (GlobeNewswire)
Sep-07-22 07:00AM	Leap Therapeutics to Participate at the Baird 2022 Global Healthcare Conference (PR Newswire) +8.02%
Sep-06-22 07:00AM	Leap Therapeutics Announces Appointment of Richard L. Schilsky, MD to its Board of Directors (PR Newswire) +8.72%
Sep-04-22 06:05PM	Leap Therapeutics to Present New Data from DisTinGuish Study of DKN-01 Plus Tislelizumab and WAKING Study of DKN-01 Plus Tecentriq® at the ESMO Congress (PR Newswire)
Aug-12-22 07:00AM	Leap Therapeutics' Board of Directors Member Dr. Monica Bertagnolli Appointed as the Director of the National Cancer Institute (PR Newswire)
07:00AM	Leap Therapeutics Reports Second Quarter 2022 Financial Results (PR Newswire)
Jul-21-22 07:47AM	Do Institutions Own Leap Therapeutics, Inc. (NASDAQ:LPTX) Shares? (Simply Wall St.)
Jul-14-22 11:37AM	Humanigen (HGEN) Plunges as COVID Study Fails to Meet Goal (Zacks)
11:34AM	Amryt (AMYT) Mycapssa Gets Orphan Drug Tag for Carcinoid Syndrome (Zacks)
Jul-12-22 11:20AM	Perrigo (PRGO) Unit Files for OTC Birth Control Pill With FDA (Zacks) -8.80%
11:13AM	Novo Nordisk's (NVO) Haemophilia A Study Meets Safety Endpoint (Zacks)
07:00AM	Leap Therapeutics Announces Initiation of New DKN-01 Clinical Trials in Gastric Cancer, Colorectal Cancer and Endometrial Cancer (PR Newswire)
Jul-11-22 11:58AM	Horizon (HZNP) Gets FDA Nod for Krystexxa's Label Expansion (Zacks) -6.72%
06:19AM	Zacks.com featured highlights include Boot Barn, Canada Goose, Pediatrix Medical Group, Leap Therapeutics and Oncolytics Biotech (Zacks)
Jul-08-22 11:48AM	Editas (EDIT) Focuses on Developing Gene-Editing Eye Drug (Zacks)
11:14AM	Acadia (ACAD) Down More Than 30% in Past 3 Months: Here's Why (Zacks)
Jul-07-22 11:22AM	Adverum (ADVM) Completes IND Amendment for Gene Therapy Study (Zacks)
Jul-04-22 11:49AM	Celldex (CLDX) Down on Interim Data From Phase Ib Study in CSU (Zacks)
Jun-29-22 12:44PM	Seagen (SGEN) Up More Than 20% in Past 3 Months: Here's Why (Zacks)
12:34PM	Graybug (GRAY) to Review Strategic Alternatives, Stock Up (Zacks)
Jun-28-22 11:52AM	Cybin (CYBN) Up on FDA Clearance of IND for CYB003 in MDD (Zacks) -6.82%
Jun-27-22 07:00AM	Leap Therapeutics to Host Virtual R&D Day on July 12, 2022 (PR Newswire) +9.09%
Jun-17-22 11:16AM	Blueprint Medicines' (BPMC) Ayvakit Aids Growth Amid Rivalry (Zacks)
Jun-13-22 12:01PM	Immunovant (IMVT) Set on Lead Candidate Batoclimab's Development (Zacks) -6.54%
Jun-10-22 10:51AM	Alnylam (ALNY) Posts Positive Data From IgA Nephropathy Study (Zacks)
Jun-09-22 10:48AM	Immunovant (IMVT) Sees Wider Q4 Loss, to Study Batoclimab in TED (Zacks) -6.67%
Jun-08-22 10:14AM	Apellis (APLS), Sobi Begin Pegcetacoplan Dosing in Kidney Disease (Zacks) +10.09%
Jun-07-22 11:30AM	Praxis (PRAX) Tanks on Negative Data From Depression Study (Zacks)
11:23AM	Global Blood's (GBT) Candidates for SCD Get Two FDA Tags (Zacks)
Jun-06-22 10:13AM	GSK Gets FDA Nod for Measles, Mumps & Rubella Vaccine, Priorix (Zacks) -6.84%

Cypherpunk Technologies, Inc. is a clinical-stage biopharmaceutical company focused on developing targeted and immuno-oncology therapeutics. Its novel therapies are designed to treat patients with cancer. The company was founded on January 3, 2011 and is headquartered in Cambridge, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Mirabelli Christopher	Director	Nov 17 '25	Sale	3.14	676,319	2,123,642	2,136	Nov 19 04:06 PM
CAVANAUGH JAMES H	Director	Nov 17 '25	Sale	3.14	261,840	822,178	0	Nov 19 04:05 PM
ONSI DOUGLAS E	CEO,CFO,Pres.,GC,Treas.&Sec.	Nov 17 '25	Sale	3.14	676,319	2,123,642	2,136	Nov 19 04:05 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Black Swan Sale

50% Off Elite

CYPH

Cypherpunk Technologies Inc

Upgrade your FINVIZ experience